The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report

ABSTRACT Background The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23–25, 2025. Methods The Annual PCF Scientific Retreat is a global forum for presenting the newest basic, translational, and clinical discoveries in prostate cancer, alongside work from related fields. Presentations highlight discoveries with strong potential to advance prostate cancer understanding, change clinical practice, and improve patient outcomes. Results The 2025 PCF Retreat featured research and special lectures from many disciplines, including: (i) next‐generation theranostics; (ii) emerging immunotherapy approaches in prostate cancer; (iii) understanding and drugging the epigenome; (iv) clinical trial updates; (v) artificial intelligence (AI) and machine learning; (vi) circulating biomarkers; (vii) harnessing the host microbiome in cancer; (viii) exercise interventions for patients with prostate cancer; (ix) CYP17A1‐independent androgen biosynthesis as a mechanism of persistent androgen production; (x) Prostate Cancer Working Group 4 recommendations for trial design and response assessment; (xi) tissue‐guided optimization of combination therapy; (xii) PCF Women in Science Lifetime Achievement Award lecture; and (xiii) bridging biomedical research and drug development. Conclusions The 2025 PCF Scientific Retreat illustrated how advances across diverse fields, including theranostics, immunotherapy, epigenetics, AI, and liquid biopsy, are converging to reshape how prostate cancer is understood, monitored, and treated. Recurring themes included tumor heterogeneity and lineage plasticity as determinants of treatment response, the need for predictive biomarkers to guide increasingly intensive and combination therapies, and the movement of effective therapies into earlier disease settings. This report reflects the state of the science as of October 2025.

Authors

Institutions

Publication Details

Journal
The Prostate
Published
2026-11-17
DOI
https://doi.org/10.1002/pros.70276
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report

Phillip J. Koo, Andrea K. Miyahira
The Prostate
Prostate Cancer Treatment and Research
article

The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report

Phillip J. Koo, Andrea K. Miyahira
article en

Abstract

ABSTRACT Background The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23–25, 2025. Methods The Annual PCF Scientific Retreat is a global forum for presenting the newest basic, translational, and clinical discoveries in prostate cancer, alongside work from related fields. Presentations highlight discoveries with strong potential to advance prostate cancer understanding, change clinical practice, and improve patient outcomes. Results The 2025 PCF Retreat featured research and special lectures from many disciplines, including: (i) next‐generation theranostics; (ii) emerging immunotherapy approaches in prostate cancer; (iii) understanding and drugging the epigenome; (iv) clinical trial updates; (v) artificial intelligence (AI) and machine learning; (vi) circulating biomarkers; (vii) harnessing the host microbiome in cancer; (viii) exercise interventions for patients with prostate cancer; (ix) CYP17A1‐independent androgen biosynthesis as a mechanism of persistent androgen production; (x) Prostate Cancer Working Group 4 recommendations for trial design and response assessment; (xi) tissue‐guided optimization of combination therapy; (xii) PCF Women in Science Lifetime Achievement Award lecture; and (xiii) bridging biomedical research and drug development. Conclusions The 2025 PCF Scientific Retreat illustrated how advances across diverse fields, including theranostics, immunotherapy, epigenetics, AI, and liquid biopsy, are converging to reshape how prostate cancer is understood, monitored, and treated. Recurring themes included tumor heterogeneity and lineage plasticity as determinants of treatment response, the need for predictive biomarkers to guide increasingly intensive and combination therapies, and the movement of effective therapies into earlier disease settings. This report reflects the state of the science as of October 2025.

The Prostate
Prostate Cancer Foundation (US)
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon